Renal Molecular Imaging of Mesangial Cell Function with Tc-99m-Tilmanocept
使用 Tc-99m-Tilmanocept 对系膜细胞功能进行肾脏分子成像
基本信息
- 批准号:10375348
- 负责人:
- 金额:$ 62.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:Adverse eventAlbuminuriaBindingBiodistributionBiological MarkersBladderBloodCell physiologyCell surfaceChemicalsChronic Kidney FailureClinicalClinical TrialsClinical Trials DesignClinical trial protocol documentCreatinineDataDevelopmentDiabetes MellitusDiabetic NephropathyDiabetic mouseDiagnosisDiagnosticDiagnostic testsDiscipline of Nuclear MedicineDiseaseDisease modelDoseDrug KineticsEarly DiagnosisEarly treatmentEffective Renal Plasma FlowEuropeanEvaluationFutureGlomerular Filtration RateGlomerular Mesangial CellHalf-LifeHeartHepatocyteHistologicHumanHypertensionImageIndividualInternationalIntervention TrialIntravenousJournalsKidneyKidney DiseasesKineticsLaboratoriesLaboratory StudyLiverMolecularMotivationPathologyPatientsPeriodicityPersonsPhase I Clinical TrialsPlasmaPositron-Emission TomographyPrevalenceProtocols documentationPublishingRadiolabeledRadiopharmaceuticalsRattusRenal HypertensionRiskSafetySamplingScanningSerumSpecificitySurfaceTechnetium 99mTestingTherapeutic InterventionTimeUrinebasedb/db mousedesigndiabeticdiabetic patientdrug developmentfirst-in-humanglomerular filtrationhigh riskimaging agentimaging biomarkerkidney cortexkidney imagingkidney medullamacrophagemesangial cellmicroPETmolecular imagingnuclear imagingopen labelphase I trialradiation absorbed doseresearch clinical testingsingle photon emission computed tomographystandard of caretool
项目摘要
In 2017 the International Diabetes Federation estimated that the worldwide prevalence of diabetes would
increase from 415 million in 2015 to 642 million in 2040. Approximately 40% of individuals with diabetes
develop diabetic nephropathy (DN). Twenty percent of these individuals do not follow the typical path toward
chronic kidney disease, which is a slow multi-decade increase in albuminuria and serum creatinine, the current
standard-of-care for surveillance of chronic kidney disease (KD). Consequently, there is an unmet clinical need
for routine surveillance during the first decade of chronic KD.
We propose external imaging of mesangial cell function as a biomarker for diabetic nephropathy. Our
reasoning is based on the following. Mesangial cell matrix (MCM) expansion is a histologic hallmark of diabetic
nephropathy, which precedes the reduction of a patient’s glomerular filtration rate or increase in albuminuria.
Additionally, all the clinical manifestations of diabetic nephropathy are highly correlated with MCM expansion.
There currently does not exist an imaging, serum, or urine biomarker that is sensitive to mesangial cell
function. Current imaging agents and biomarkers are only sensitive to glomerular filtration, effective renal
plasma flow, or albuminuria, which are altered late in the disease when therapeutic intervention is not effective.
We propose a Phase 1 clinical trial of Tc-99m-tilmanocept, which accumulates in the liver and kidneys. The
molecular mechanism is binding to CD206, which resides on the cell surface of fixed macrophages within the
liver and mesangial cells within the kidney. We present preliminary data consisting of human SPECT/CT and
rat microPET images of renal cortex. Additionally, we present evidence of sensitivity to MCM expansion via Tc-
99m-tilmanocept dynamic imaging of db/db mice, an accepted disease model of diabetic nephropathy.
We propose an open-label study to investigate the biodistribution at two dose levels (2.0 & 20 nmol) of Tc-
99m-tilmanocept. We will study 5 groups at each dose (10 subjects each): 1) Advance DN, 2) early DN, 3)
diabetes with no kidney disease, 4) advanced hypertension (HTN) with KD, and 5) HTN without KD. The study
will include a 30-min dynamic followed be a 30-min kidney SPECT/CT, and periodic blood and urine sampling.
Dynamic imaging will yield plasma clearance half-lifes, and liver and kidney accumulation rates; SPECT/CT will
yield SUVs for the heart, liver, renal cortex, renal medulla. We will also calculate urinary bladder accumulation.
We expect the renograms and biodistribution data to reflect the following pathology: Group 1, severe MCM
expansion; G2, mild MCM expansion; G3 & G5, no MCM expansion; and G4, low MCM expansion.
This study is the necessary first step toward FDA-approval of Tc-99m-tilmancoept as a kidney imaging
agent. The study will also provide evidence of imaging sensitivity to MCM expansion in DN patients, and
insensitivity to patients with HTN. This senerio will be required if Tc-99m-tilmanocept renograms as “first-line”
diagnostic test for diabetic patients.
2017年,国际糖尿病联合会估计,全球糖尿病患病率将
从2015年的4.15亿增加到2040年的6.42亿。大约40%的糖尿病患者
发生糖尿病肾病(DN)。这些人中有20%不遵循典型的道路,
慢性肾脏疾病,这是一个缓慢的几十年增加的蛋白尿和血清肌酐,目前
慢性肾病(KD)监测的护理标准。因此,存在未满足的临床需求
在慢性KD的前十年进行常规监测。
我们建议将系膜细胞功能的外部成像作为糖尿病肾病的生物标志物。我们
推理基于以下内容。系膜细胞基质(MCM)扩张是糖尿病肾病的组织学标志,
肾病,其先于患者的肾小球滤过率降低或白蛋白尿增加。
此外,糖尿病肾病的所有临床表现与MCM扩张高度相关。
目前不存在对系膜细胞敏感的成像、血清或尿液生物标志物
功能目前的显像剂和生物标志物仅对肾小球滤过敏感,有效的肾功能损害是不可逆的。
血浆流量或白蛋白尿,当治疗干预无效时,其在疾病后期发生改变。
我们提出了一项Tc-99 m-tilmanocept的1期临床试验,它在肝脏和肾脏中积累。的
分子机制是与CD 206结合,CD 206位于细胞内固定的巨噬细胞的细胞表面。
肝脏和肾脏内的系膜细胞。我们目前的初步数据包括人体SPECT/CT和
大鼠肾皮质的microPET图像。此外,我们提出的证据的敏感性MCM膨胀通过Tc-
db/db小鼠(一种公认的糖尿病肾病疾病模型)的99 m-tilmanocept动态成像。
我们提出了一个开放标签的研究,以调查在两个剂量水平(2.0和20 nmol)的Tc的生物分布。
99m-tilmanocept。我们将在每个剂量下研究5组(每组10名受试者):1)晚期DN,2)早期DN,3)
无肾脏疾病的糖尿病,4)有KD的晚期高血压(HTN),和5)无KD的HTN。研究
将包括30分钟动态,随后是30分钟肾脏SPECT/CT,以及定期血液和尿液采样。
动态成像将产生血浆清除半衰期以及肝脏和肾脏蓄积率; SPECT/CT将
产生心脏、肝脏、肾皮质、肾髓质的SUV。我们还将计算膀胱积聚。
我们期望肾图和生物分布数据反映以下病理:第1组,重度MCM
扩展; G2,轻度MCM扩展; G3和G5,无MCM扩展; G4,低MCM扩展。
这项研究是FDA批准Tc-99 m-tilmancoept作为肾脏成像的必要的第一步。
剂该研究还将提供DN患者中MCM扩张的成像敏感性证据,
对HTN患者不敏感。如果将Tc-99 m-tilmanocept肾图作为“一线”肾图,则需要此服务。
糖尿病患者的诊断测试。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES GINSBERG其他文献
CHARLES GINSBERG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES GINSBERG', 18)}}的其他基金
Renal Molecular Imaging of Mesangial Cell Function with Tc-99m-Tilmanocept
使用 Tc-99m-Tilmanocept 对系膜细胞功能进行肾脏分子成像
- 批准号:
10733137 - 财政年份:2021
- 资助金额:
$ 62.7万 - 项目类别:
Influence of Vitamin D Binding Protein on Clinical Measures of Vitamin D Status and Bone Health
维生素 D 结合蛋白对维生素 D 状态和骨骼健康临床指标的影响
- 批准号:
10394279 - 财政年份:2018
- 资助金额:
$ 62.7万 - 项目类别:
Influence of Vitamin D Binding Protein on Clinical Measures of Vitamin D Status and Bone Health
维生素 D 结合蛋白对维生素 D 状态和骨骼健康临床指标的影响
- 批准号:
9910387 - 财政年份:2018
- 资助金额:
$ 62.7万 - 项目类别:
相似海外基金
Albuminuria and vascular risk in females with chronic kidney disease
女性慢性肾病患者的蛋白尿和血管风险
- 批准号:
481013 - 财政年份:2023
- 资助金额:
$ 62.7万 - 项目类别:
Molecular mechanisms of heparanase-2 (hpa-2) in endothelial cell activation, inflammation and albuminuria
乙酰肝素酶 2 (hpa-2) 在内皮细胞活化、炎症和蛋白尿中的分子机制
- 批准号:
389250244 - 财政年份:2017
- 资助金额:
$ 62.7万 - 项目类别:
Research Grants
Albuminuria and incident chronic lung disease exacerbations in five population-based cohorts
五个基于人群的队列中的蛋白尿和慢性肺病恶化事件
- 批准号:
9144859 - 财政年份:2015
- 资助金额:
$ 62.7万 - 项目类别:
The association between changes in albuminuria and all-cause mortality in patients with type 2 diabetes in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) Study
糖尿病和血管疾病行动:preterAx 和 diamicroN-MR 对照评估 (ADVANCE) 研究中白蛋白尿变化与 2 型糖尿病患者全因死亡率之间的关联
- 批准号:
324375 - 财政年份:2015
- 资助金额:
$ 62.7万 - 项目类别:
Albuminuria and incident chronic lung disease exacerbations in five population-based cohorts
五个基于人群的队列中的蛋白尿和慢性肺病恶化事件
- 批准号:
8997288 - 财政年份:2015
- 资助金额:
$ 62.7万 - 项目类别:
The Role of Nontraditional Glycemic Markers in Diabetes and Albuminuria
非传统血糖标志物在糖尿病和蛋白尿中的作用
- 批准号:
9028606 - 财政年份:2013
- 资助金额:
$ 62.7万 - 项目类别:
The Role of Nontraditional Glycemic Markers in Diabetes and Albuminuria
非传统血糖标志物在糖尿病和蛋白尿中的作用
- 批准号:
8508005 - 财政年份:2013
- 资助金额:
$ 62.7万 - 项目类别:
Investigation of pathogenesis of albuminuria in chronic kidney disease and its association with cardiovascular complications
慢性肾脏病白蛋白尿发病机制及其与心血管并发症的关系研究
- 批准号:
23591209 - 财政年份:2011
- 资助金额:
$ 62.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The association of sub-clinical atherosclerosis and estimated glomelular filtration rate with albuminuria among general Japanese.
日本普通人群亚临床动脉粥样硬化和估计肾小球滤过率与蛋白尿的关联。
- 批准号:
23590791 - 财政年份:2011
- 资助金额:
$ 62.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of mechanism of albuminuria/proteinuria in diabetes in terms of sugar chain
从糖链角度分析糖尿病白蛋白尿/蛋白尿机制
- 批准号:
22790788 - 财政年份:2010
- 资助金额:
$ 62.7万 - 项目类别:
Grant-in-Aid for Young Scientists (B)














{{item.name}}会员




